8-K: Xilio Therapeutics Announces Results of 2024 Annual Stockholders Meeting
Annual Meeting Results
Xilio Therapeutics held its 2024 annual meeting of stockholders on June 13, 2024, where directors were elected and the company's accounting firm was ratified.
Summary
- Xilio Therapeutics held its 2024 annual meeting of stockholders on June 13, 2024.
- At the meeting, stockholders elected Paul J. Clancy and Christina Rossi as Class III directors, each for a three-year term expiring at the 2027 annual meeting.
- The stockholders also ratified the selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
Sentiment
Score: 7
Explanation: The document reflects standard corporate governance procedures and does not contain any unexpected or negative information. The sentiment is neutral to slightly positive due to the successful completion of the meeting.
Positives
- The election of directors and ratification of the accounting firm were successfully completed.
- The high number of votes in favor of the director elections and the accounting firm ratification indicates strong shareholder support.
Industry Context
This announcement is a routine corporate governance update, typical for publicly traded companies following their annual shareholder meetings. It ensures compliance with regulatory requirements and provides transparency to investors.
Comparison to Industry Standards
- The election of directors and ratification of auditors are standard practices for publicly traded companies like Xilio Therapeutics.
- The voting results are typical for such meetings, with a majority of votes cast in favor of the proposed resolutions.
- Companies like Amgen, Regeneron, and Gilead also conduct similar annual meetings with similar voting procedures.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class III Director | NA | Paul J. Clancy | June 13, 2024 | Election at annual meeting |
| Class III Director | NA | Christina Rossi | June 13, 2024 | Election at annual meeting |
Stakeholder Impact
- Shareholders have successfully exercised their voting rights.
- The company has fulfilled its corporate governance obligations.
Key Dates
| Date | Description |
|---|---|
| June 13, 2024 | Date of the 2024 annual meeting of stockholders. |
| June 17, 2024 | Date the 8-K report was signed. |
| December 31, 2024 | End of the fiscal year for which Ernst & Young LLP was ratified as the accounting firm. |
| 2027 | Year the terms of the newly elected Class III directors expire. |
Keywords
Annual Meeting, Stockholders, Directors, Accounting Firm, Corporate Governance, Xilio Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.